Net margin is calculated as Net Income divided by its Revenue. RaQualia Pharma's Net Income for the
three
months ended in Mar. 2026 was 円-226 Mil. RaQualia Pharma's Revenue for the
three
months ended in Mar. 2026 was 円802 Mil. Therefore, RaQualia Pharma's net margin for the quarter that ended in Mar. 2026 was -28.14%.
The historical rank and industry rank for RaQualia Pharma's Net Margin % or its related term are showing as below:
TSE:4579'
s Net Margin % Range Over the Past 10 Years
Min: -148.36 Med: -10.02 Max: 27.22
Current: -41.91
TSE:4579's Net Margin % is ranked better than 57.1% of 937
companies
in the Biotechnology industry
Industry Median: -88.29
vs TSE:4579: -41.91
RaQualia Pharma (TSE:4579) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
RaQualia Pharma Net Margin % Related Terms
RaQualia Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, RaQualia Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Net Margin % of -28.14% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on RaQualia Pharma and its competitors. According to the industry distribution chart, RaQualia Pharma ranks #402 out of 937 companies in the Biotechnology industry, placing it in the top 42.9%.
Is RaQualia Pharma's Net Margin % too high?
RaQualia Pharma's current Net Margin % is -28.14%. Based on the distribution chart, RaQualia Pharma ranks #402 out of 937 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #402 out of 937 companies for Net Margin %. This puts RaQualia Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Net Margin % is -28.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Net Margin % is -28.14%. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Net Margin % is -28.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31.
GuruFocus considers RaQualia Pharma to be Significantly Undervalued.
Key valuation signals for TSE:4579:
Net Margin %: -28.14%
GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score
Get the complete analysis for TSE:4579
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
